Silence Therapeutics nets important patent in Europe

Silence Therapeutics strengthen the protection for its innovative chemical modification technology in Europe, as the European Patent Office granted it a further European patent EP 1857547B.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, says that the newly granted claims add further value to the company’s intellectual property portfolio, and strengthen our patent position in Europe.”

Silence seeks to protect the value of its portfolio and investment, where necessary using all the legal means at its disposal, it was said in the company’s announcement on Monday. It didn’t say what exactly

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Image: Ali Mortazavi, Chief Executive Officer of Silence Therapeutics